Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL)

被引:13
作者
Liu, Bin [1 ]
Li, Bo [2 ]
Zhou, Pingting [3 ]
Yue, Wenqin [1 ]
Wang, Tao [1 ]
Wang, Jianmin [1 ]
Hu, Xiaoxia [1 ]
Zhang, Weiping [1 ]
Chen, Jie [1 ]
Chen, Li [1 ]
Gao, Lei [1 ]
He, Miaoxia [4 ]
Yang, Jianmin [1 ]
机构
[1] Second Mil Med Univ, Changhai Hosp, Dept Hematol, Shanghai 200933, Peoples R China
[2] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Dept Radiat Oncol, Shanghai Peoples Hosp 9, Shanghai, Peoples R China
[4] Second Mil Med Univ, Changhai Hosp, Dept Pathol, Shanghai 200433, Peoples R China
关键词
D-dimer; Prognostic marker; Diffuse large B cell lymphoma (DLBCL); Survival; COLORECTAL-CANCER; PROSTATE-CANCER; LUNG-CANCER; SOLUBLE INTERLEUKIN-2-RECEPTOR; FIBRINOLYTIC PROFILES; ACTIVATION MARKERS; PLUS RITUXIMAB; BREAST-CANCER; TUMOR STAGE; COAGULATION;
D O I
10.1016/j.cca.2018.04.013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background. We assessed the prognostic significance of D-dimer in patients of diffuse large B cell lymphoma (DLBCL). Methods: We performed a retrospective study including 254 patients who were newly diagnosed DLBCL. X-tile was used to generate a cutoff value for D-dimer. Both univariate screen by Cox proportional hazard model and multivariable analysis by Cox regression model were used to assess the impact of pretreatment D-dimer levels on the overall survival (OS). Result: According to X-tile, the optimal cut-off value of D-dimer for prediction of survival was set as 1.6 mu g/mL, and a D-dimer level >= 1.6 mu g/mL was significantly associated with poor overall survival (OS) (OS: 31.7 vs. 79.1%, P < 0.001). In multivariable analysis, it was found that a higher D-dimer level was an independent predictor for worse OS (Hazard ratio (HR): 3.594 95% Confidence interval (CI): 2.296-5.267, P < 0.001). In subgroup analysis of International Prognostic Index (IPI), survival of low-risk and intermediate-risk group with a D-dimer level >= 1.6 mu g/mL were both similar to that of the high-risk group (OS: 31.6 vs. 36.5%, P = 0.957; OS: 38.0 vs. 36.5%, P = 0.758). In addition, among patients treated with surgery, those with higher D-dimer had substantially worse survival than that with lower D-dimer (OS: 27.0 vs. 84.5%, P < 0.001). Conclusion: Pretreatment D-dimer is a simple but effective predictor of survival among patients with DLBCL.
引用
收藏
页码:191 / 198
页数:8
相关论文
共 48 条
[1]  
ADAMSON AS, 1993, ANN ROY COLL SURG, V75, P100
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]  
Bi X. W., 2016, PLOS ONE, P11
[4]   DIAGNOSTIC EFFICACY OF THE D-DIMER ASSAY IN DISSEMINATED INTRAVASCULAR COAGULATION (DIC) [J].
BICK, RL ;
BAKER, WF .
THROMBOSIS RESEARCH, 1992, 65 (06) :785-790
[5]   Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status [J].
Blackwell, K ;
Haroon, Z ;
Broadwater, G ;
Berry, D ;
Harris, L ;
Iglehart, JD ;
Dewhirst, M ;
Greenberg, C .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :600-608
[6]   Cancer and thrombosis: from molecular mechanisms to clinical presentations [J].
Buller, H. R. ;
Van Doormaal, F. F. ;
Van Sluis, G. L. ;
Kamphuisen, P. W. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 :246-254
[7]   X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization [J].
Camp, RL ;
Dolled-Filhart, M ;
Rimm, DL .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7252-7259
[8]   Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma [J].
Cao, Ye ;
Shi, Yan-xia ;
Chen, Jing-ou ;
Tan, Yu-ting ;
Cai, Yu-Chen ;
Luo, Hui-yan ;
Qiu, Miao-zhen ;
Cai, Xiu-yu ;
Jin, Ying ;
Sun, Yue-li ;
Jiang, Wen-qi .
TUMOR BIOLOGY, 2012, 33 (04) :1039-1044
[9]  
Chan WC, 1997, BLOOD, V89, P3909
[10]  
DEVINE DV, 1986, BLOOD, V68, P317